NCT07889102
Impact of Telepharmacy on Hemodialysis Outcomes
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (1)
Arms and interventions
Participants assigned to this arm received routine hemodialysis care according to standard clinical practice without additional telepharmacy support. This included regular physician follow-up, laboratory monitoring, and medication management as determined by the treating healthcare team. No structured pharmacist-led remote monitoring or scheduled telecommunication-based interventions were provided.
Participants assigned to this arm received routine maintenance hemodialysis care in addition to a structured telepharmacy intervention delivered by trained clinical pharmacists over a 5-month period. The intervention included scheduled telephone follow-up, medication review, adherence assessment, individualized counseling, monitoring of laboratory results, identification and resolution of drug-related problems, and collaboration with treating physicians to optimize erythropoiesis-stimulating agent (ESA) therapy and overall medication management.
Other: Routine Standard Care
Behavioral: Telepharmacy Intervention
Sites
2 sites in 1 country